Free Industrial News

Feds Halt Production at Emergent BioSolution's COVID-19 Vaccine Plant in Baltimore

Feds Halt Production at Emergent BioSolution's COVID-19 Vaccine Plant in Baltimore

pharmaceutical

Industry Segment: Pharmaceutical & Biotech | Word Count: 124 Words

SUGAR LAND--April 23, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--Armed with a list of manufacturing violations, the Food and Drug Administration (FDA) has halted production at contract manufacturer (CMO) Emergent BioSolution's Bayview plant in Baltimore, Maryland. In addition, 60 million doses of the Johnson & Johnson (NYSE:JNJ) "one-shot" COVID-19 vaccines have been quarantined, meaning the bulk drug product will not be shipped to a fill-and-finish facility for completion.

Companies featured: Johnson & Johnson (NYSE:JNJ)

Subscribe Now!(All Fields Required)

Standard Membership - Free